Chris Schott
Stock Analyst at JP Morgan
(3.67)
# 773
Out of 4,966 analysts
134
Total ratings
61.11%
Success rate
3.66%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Reiterates: Overweight | $1,100 | $732.58 | +50.15% | 21 | Aug 8, 2025 | |
| PRGO Perrigo Company | Maintains: Overweight | $38 → $35 | $23.74 | +47.43% | 12 | Aug 7, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $550 → $675 | $647.09 | +4.31% | 8 | Aug 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $950 → $800 | $580.70 | +37.76% | 8 | Jun 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Overweight | $21 → $23 | $18.38 | +25.14% | 16 | May 12, 2025 | |
| BIIB Biogen | Maintains: Neutral | $185 → $175 | $132.22 | +32.36% | 4 | May 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $130 | $112.97 | +15.07% | 6 | Mar 27, 2025 | |
| AMRX Amneal Pharmaceuticals | Upgrades: Overweight | $9 → $12 | $9.56 | +25.52% | 2 | Feb 24, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $200 | $210.40 | -4.94% | 2 | Nov 13, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $156.40 | +47.06% | 2 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $20 | $9.42 | +112.31% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $35.98 | +16.73% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $287.71 | -6.16% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $24.76 | +37.32% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $84.12 | +48.60% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $10.55 | +32.70% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.16 | +848.28% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $18.35 | +8.99% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.42 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $47.18 | +65.32% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $11.22 | +8,367.02% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.11 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $26.67 | +87.48% | 3 | Nov 2, 2018 |
Eli Lilly and Company
Aug 8, 2025
Reiterates: Overweight
Price Target: $1,100
Current: $732.58
Upside: +50.15%
Perrigo Company
Aug 7, 2025
Maintains: Overweight
Price Target: $38 → $35
Current: $23.74
Upside: +47.43%
IDEXX Laboratories
Aug 4, 2025
Maintains: Overweight
Price Target: $550 → $675
Current: $647.09
Upside: +4.31%
Regeneron Pharmaceuticals
Jun 9, 2025
Maintains: Overweight
Price Target: $950 → $800
Current: $580.70
Upside: +37.76%
Teva Pharmaceutical Industries
May 12, 2025
Upgrades: Overweight
Price Target: $21 → $23
Current: $18.38
Upside: +25.14%
Biogen
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $132.22
Upside: +32.36%
Gilead Sciences
Mar 27, 2025
Maintains: Overweight
Price Target: $120 → $130
Current: $112.97
Upside: +15.07%
Amneal Pharmaceuticals
Feb 24, 2025
Upgrades: Overweight
Price Target: $9 → $12
Current: $9.56
Upside: +25.52%
AbbVie
Nov 13, 2024
Maintains: Overweight
Price Target: $210 → $200
Current: $210.40
Upside: -4.94%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $156.40
Upside: +47.06%
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $9.42
Upside: +112.31%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $35.98
Upside: +16.73%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $287.71
Upside: -6.16%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $24.76
Upside: +37.32%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $84.12
Upside: +48.60%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $10.55
Upside: +32.70%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.16
Upside: +848.28%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $18.35
Upside: +8.99%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $7.42
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $47.18
Upside: +65.32%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $11.22
Upside: +8,367.02%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.11
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $26.67
Upside: +87.48%